GSK’s new chief executive, Luke Miels, outlined a strategic shift on July 28, 2026, aimed at reshaping the U.K. pharmaceutical company into a faster, more agile organization. Reporting from London, Andrew Joseph noted that Miels is roughly six months into the role and framed the plans as a multi‑year effort to position the company for future growth.
Miels described the approach as a step‑by‑step effort to build a portfolio of potential best‑in‑class products across GSK’s core therapy areas. He emphasized agility and speed in company operations as central objectives of the strategy.
A core element of the plan is a three‑year campaign to deliver £1.9 billion in annual savings by 2029. Miels said much of those savings will be reinvested into advancing the company’s late‑stage pipeline. The article did not provide a detailed breakdown of where savings would be found or specific line items targeted for reduction.
The company framed the savings program as a way to free up capital to accelerate development of late‑stage assets, but the source did not report precise reinvestment amounts, timelines for allocation, or which R&D programs would receive priority funding.
As part of the shift toward a more development‑focused company, GSK now plans to initiate at least 20 Phase 3 trials this year. That commitment represents an increase from the 10 Phase 3 trials the company had publicly disclosed at the start of 2026.
The announcement signals a tangible escalation of late‑stage clinical activity intended to move more programs toward potential registration and commercialization. The source did not list the individual trials, indications, or expected start dates beyond the statement that the company will start at least 20 Phase 3 studies this year.
Miels identified a mix of longstanding and newer areas of emphasis for GSK’s pipeline. Longtime company strengths include vaccines and HIV, while newer or expanded focuses cited by Miels include oncology and liver disease. He framed these as core therapy areas where the company is building potential best‑in‑class products.
Beyond naming those therapy areas, the article did not provide details about specific programs, mechanisms of action, compounds, or clinical indications within oncology or liver disease that will be prioritized.
When asked about the human impact of the savings campaign, Miels declined to specify how many jobs would be cut. The article therefore records the company’s significant cost‑saving objective but notes that details on workforce consequences were not disclosed.
Other granular operational details are similarly absent from the report: no specific examples of cost‑reduction measures, organizational changes, or timelines for workforce actions were provided in the source material.
This coverage is drawn from a STAT report by Andrew Joseph on July 28, 2026. Portions of the original article are behind the STAT+ subscriber paywall; the published excerpt contains the principal strategic announcements but does not include additional subscriber‑only specifics. Where the source did not report details — for example, exact job‑cut numbers, trial identifiers, or the full reinvestment allocation plan — those items are noted here as not reported.
Summary
In sum, under Luke Miels GSK is pursuing a twin strategy of aggressive cost savings and expanded late‑stage clinical investment: a three‑year program to achieve £1.9 billion in annual savings by 2029, and an elevated target to begin at least 20 Phase 3 trials this year, with emphasis on vaccines, HIV, oncology, and liver disease. The company has not disclosed the scale of workforce reductions or the specific trials and programs that will be advanced with the savings.